Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-RiskAssessment

More Like This

PR Newswire associated0

EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PR Newswire associated0

EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

PR Newswire associated0

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

PR Newswire associated0

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PR Newswire associated0

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

SISCAPA and Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma